Agile Therapeutics Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Agile Therapeutics stock.
View analyst ratings for Agile Therapeutics or view top-rated stocks.

Wall Street analysts have given Agile Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Agile Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Agile Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Agile Therapeutics.

Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its quarterly earnings results on Monday, May, 3rd. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. The specialty pharmaceutical company earned $0.12 million during the quarter, compared to analysts' expectations of $0.65 million.
View Agile Therapeutics' earnings history.

Agile Therapeutics' stock was trading at $1.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AGRX shares have decreased by 27.3% and is now trading at $1.41.
View which stocks have been most impacted by COVID-19.

5 brokers have issued 1 year target prices for Agile Therapeutics' stock. Their forecasts range from $6.00 to $8.00. On average, they expect Agile Therapeutics' share price to reach $7.25 in the next twelve months. This suggests a possible upside of 414.2% from the stock's current price.
View analysts' price targets for Agile Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Agile Therapeutics include Basilea Pharmaceutica (BPMUF), Vaccitech (VACC), SIGA Technologies (SIGA), Viking Therapeutics (VKTX), XBiotech (XBIT), Molecular Templates (MTEM), Landos Biopharma (LABP), Nabriva Therapeutics (NBRV), Greenwich LifeSciences (GLSI), Viracta Therapeutics (VIRX), TherapeuticsMD (TXMD), CytomX Therapeutics (CTMX), Gemini Therapeutics (GMTX), Avadel Pharmaceuticals (AVDL) and Flexion Therapeutics (FLXN).
View all of AGRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Agile Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.78%), Geode Capital Management LLC (1.40%), Royal Bank of Canada (1.06%), Northern Trust Corp (0.84%), First Midwest Bank Trust Division (0.66%) and Renaissance Technologies LLC (0.43%). Company insiders that own Agile Therapeutics stock include Alfred Altomari, Dennis Reilly, Jason Butch, Life Sciences Maste Perceptive and Perceptive Advisors Llc.
View institutional ownership trends for Agile Therapeutics.

AGRX stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Premier Asset Management LLC, Morgan Stanley, Northern Trust Corp, BlackRock Inc., New York State Common Retirement Fund, JPMorgan Chase & Co., and D. E. Shaw & Co. Inc..
View insider buying and selling activity for Agile Therapeutics or view top insider-selling stocks.

AGRX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Royal Bank of Canada, GSA Capital Partners LLP, Geode Capital Management LLC, Cubist Systematic Strategies LLC, Price T Rowe Associates Inc. MD, M Holdings Securities Inc., and Barclays PLC. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari, Dennis Reilly, Jason Butch, Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Agile Therapeutics or or view top insider-buying stocks.

Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGRX stock can currently be purchased for approximately $1.41.

Agile Therapeutics has a market capitalization of $124.45 million and generates $750,000.00 in revenue each year. The specialty pharmaceutical company earns $-51,850,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

Agile Therapeutics employs 28 workers across the globe.

The official website for Agile Therapeutics is www.agiletherapeutics.com.

Agile Therapeutics is headquartered at 101 POOR FARM ROAD, PRINCETON NJ, 08540.

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]